MARKET

MAZE

MAZE

Maze Therapeutics
NASDAQ
11.62
+0.63
+5.73%
Opening 10:59 03/17 EDT
OPEN
10.85
PREV CLOSE
10.99
HIGH
11.97
LOW
9.88
VOLUME
16.95K
TURNOVER
--
52 WEEK HIGH
17.00
52 WEEK LOW
9.88
MARKET CAP
497.65M
P/E (TTM)
-17.5396
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MAZE last week (0303-0307)?
Weekly Report · 03/10 12:59
Weekly Report: what happened at MAZE last week (0224-0228)?
Weekly Report · 03/03 12:57
BUZZ-U.S. STOCKS ON THE MOVE-Maze Therapeutics, UFP Technologies, Itron
Reuters · 02/25 19:44
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Benzinga · 02/25 18:28
BUZZ-Maze Therapeutics rises as brokerages initiate coverage post research quiet period
Reuters · 02/25 16:13
Maze Therapeutics Price Target Announced at $19.00/Share by Guggenheim
Dow Jones · 02/25 15:06
Guggenheim Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $19
Benzinga · 02/25 14:56
Block upgraded, Domino’s downgraded: Wall Street’s top analyst calls
TipRanks · 02/25 14:36
More
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.

Webull offers Maze Therapeutics, Inc. stock information, including NASDAQ: MAZE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MAZE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MAZE stock methods without spending real money on the virtual paper trading platform.